Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

Shun Lü, Jie Wang, Ying Cheng, Tony Mok, Jianhua Chang, Li Zhang, Jifeng Feng, Hai‐Yan Tu, Lin Wu, Yiping Zhang, Alexander Luft, Jianying Zhou, Zhiyong Ma, You Lü, Chengping Hu, Yuankai Shi, Kejing Ying, Hua Zhong, Elena Poddubskaya, Ross A. Soo, Yee Hong Chia, Ang Li, Amy Li, Yi‐Long Wu